Ixaltis Overview

  • Founded
  • 2012

  • Status
  • Private

  • Employees
  • 3

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 7

Ixaltis General Information


Developer of novel pharmaceutical products designed to treat disorders of the urogenital tract. The company's products include selective serotonin, reuptake inhibitor and mixed serotonin agonist-antagonist, enabling patients to improve urinary continence.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Canal Biotech 2
  • 3, rue des satellites
  • 31400 Toulouse
  • France
+33 04 00 00 00 00

Ixaltis Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ixaltis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private 01-Mar-2021 000.00 Completed Generating Revenue
3. Later Stage VC (Series A) 27-Jul-2018 00.000 000.00 0000 Completed Generating Revenue
2. Early Stage VC 27-May-2016 $9.1M $12.2M Completed Generating Revenue
1. Debt - General $3.16M $3.16M Completed Startup
To view Ixaltis’s complete valuation and funding history, request access »

Ixaltis Executive Team (5)

Name Title Board Seat Contact Info
Roberto Gradnik MD Co-Founder, Chief Executive Officer and Board Member
Elisabeth Svanberg Ph.D Chief Development Officer
Xavier Game Member of Scientific Advisory Board & Co-Founder
Pascal Rischmann Co-Founder
Stefano Palea Co-Founder
To view Ixaltis’s complete executive team members history, request access »

Ixaltis Board Members (10)

Name Representing Role Since
Benedikt Timmerman Ph.D Self Board Member 000 0000
Christian Chavy Ixaltis Chairman 000 0000
Hasnaa Hafid iXO Private Equity Board Observer 000 0000
Jean-Briac Lesne Sofimac Innovation Board Member 000 0000
Mario Caria Sofimac Investment Managers Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Ixaltis Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ixaltis Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Emergence (Incubation) Asset Manager Minority 000 0000 000000 0
UROsphere Corporation Minority 000 0000 000000 0
iXO Private Equity PE/Buyout Minority 000 0000 000000 0
Pierre Goineau Angel (individual) Minority 000 0000 000000 0
Sofimac Innovation Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Ixaltis Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 (00000 30-May-2016 000000000 Buildings and Property 0000000 0
To view Ixaltis’s complete investments history, request access »